Overview

A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds. Whether the two or three drugs listed above when given in combination can help patients with metastatic breast cancer. How long the treatment will stop the growth of the cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Carboplatin
Gemcitabine
Mitogens
Taxane
Trastuzumab